AbbVie Inc. nd partner Johnson & Johnson intend to voluntarily withdraw the accelerated approvals of their Imbruvica drug in the U.S. for patients with certain types of blood cancer, the companies said on Thursday.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-Supreme-Court-rebuffs-AbbVie-appeal-in-patent-fight-involving-AndroGel-drug-Reuters-6-21-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-04-06 18:35:422023-04-07 09:20:47JNJ, AbbVie plan to pull U.S. accelerated approvals for some blood cancer treatments
